Researchers have found that men with prostate cancer and low testosterone are more likely to see tumors under monitoring turn dangerous.
The finding recasts a low hormone reading as a possible warning sign in a disease that is often watched rather than treated right away.
Where risk appeared
Inside records from 924 men whose cancer had not spread, one low hormone reading kept matching the most severe progression.
At the University of Texas MD Anderson Cancer Center, researchers tied readings below 300 ng/dL to riskier outcomes.
From that MD Anderson group, the signal did not flag milder worsening, which suggests it may matter most in the riskiest cases.
Because the work found an association rather than proof of cause, the result points toward closer tracking, not a new reason for panic.
Decision to delay
Many men choose active surveillance, close monitoring with delayed treatment unless cancer worsens, because early prostate tumors often pose low immediate danger.
That choice can spare surgery or radiation and their lasting side effects, a point echoed in Gregg’s public comments.
“However, identifying patients at increased risk of disease progression remains a key challenge,” said Justin R. Gregg, M.D., associate professor at MD Anderson.
Trouble starts with the minority of cases that stop behaving quietly, which is why better early warning signs matter.
The cutoff clue
Urology guidelines already treat 300 ng/dL as a practical cutoff for low testosterone in clinical care.
Using that same threshold, the researchers found that about 29% of the men in their program started low.
Those patients were 60% more likely to reach Grade Group 3 – a biopsy category showing more aggressive cells – than men above it.
By contrast, the same cutoff did not clearly predict the smaller step into Grade Group 2, which narrows what the signal may mean.
Hormones and tumors
Prostate tumors often respond to androgens, male hormones that switch on growth signals in prostate cells, which is why hormone-blocking treatment can work.
That basic biology, outlined in the National Cancer Institute’s hormone therapy fact sheet, made the new result harder to ignore.
Instead, the study suggests that low circulating hormones may mark a cancer environment already acting more aggressively before major change becomes obvious.
Such a marker would not mean the hormone itself caused the danger, but it could reveal which cancers deserve closer watch.
What the numbers showed
Across the full group, 272 men started below the cutoff, giving the signal enough weight to stand apart from age alone.
Follow-up lasted a median of 46 months for men whose cancer did not worsen, which gave later trouble time to appear.
Even after accounting for body size, common blood-test results, and how much cancer the biopsy showed, the link still held.
Still, only 34 men in the low group reached that severe category, which keeps the finding important but not absolute.
How care could change
For doctors, the value of the result lies less in prediction alone than in how it could refine follow-up.
Men who start low might get biopsies, scans, or blood checks on a tighter schedule if future studies confirm the signal.
“Understanding the influence of hormonal factors on the biology of prostate cancer can help us optimize surveillance strategies,” Gregg said.
That practical use fits the study’s message: hormone status may help sort monitoring intensity without making surveillance itself look unsafe.
What remains uncertain
One caution is immediate: the study did not show that low testosterone causes aggressive cancer.
Because the researchers looked back at one group of men on surveillance, hidden differences between patients could still shape the pattern.
Earlier cases also came from years before modern imaging routinely sorted prostate cancers more precisely at the start.
Those limits mean the result is strong enough to guide questions now, but not strong enough to rewrite care by itself.
Why context counts
A low testosterone result will not tell any individual man exactly what his cancer will do next.
Doctors still weigh biopsy details, age, overall health, symptoms, and personal priorities before changing a plan.
For some patients, more testing may bring reassurance, while earlier treatment may feel like the safer choice.
That balance explains why the new marker works best as one piece of a conversation rather than a stand-alone verdict.
What comes next
Researchers now need studies that follow men forward and measure hormones on a set schedule before any cancer changes are confirmed.
Repeated morning tests would be needed because testosterone rises and falls through the day, and single readings can mislead.
Newer surveillance programs also rely more on targeted imaging and biopsies, which could reveal whether the same signal survives current practice.
If it does, one simple blood result may help separate the men who can safely wait from those who should not.
What stays clear
Low testosterone did not predict every setback, but it consistently tracked the cancers that became truly dangerous.
That makes the finding useful not as a new fear trigger, but as a clearer way to match surveillance intensity to real risk.
The study is published in The Journal of Urology.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–